Bollard Group’s Vor Biopharma VOR Stock Holding History

Bollard Group’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-23,987	Closed	-$428K	–	326
2026 Q1	$428K	Hold	23,987	–	–	0.01%	144
2025 Q4	$314K	Buy	23,987 +21,210	+764%	+$395K	0.01%	154
2025 Q3	$135K	Sell	2,777 -1	-0%	-$40	﹤0.01%	173
2025 Q2	$90K	Hold	2,778	–	–	﹤0.01%	205
2025 Q1	$40K	Hold	2,778	–	–	﹤0.01%	225
2024 Q4	$62K	Hold	2,778	–	–	﹤0.01%	211
2024 Q3	$39K	Hold	2,778	–	–	﹤0.01%	243
2024 Q2	$56K	Hold	2,778	–	–	﹤0.01%	229
2024 Q1	$132K	Hold	2,778	–	–	﹤0.01%	182
2023 Q4	$125K	Hold	2,778	–	–	﹤0.01%	181
2023 Q3	$118K	Hold	2,778	–	–	﹤0.01%	177
2023 Q2	$172K	Hold	2,778	–	–	0.01%	170
2023 Q1	$299K	Hold	2,778	–	–	0.01%	149
2022 Q4	$369K	Hold	2,778	–	–	0.01%	133
2022 Q3	$221K	Hold	2,778	–	–	0.01%	160
2022 Q2	$276K	Hold	2,778	–	–	0.01%	162
2022 Q1	$336K	Hold	2,778	–	–	0.01%	192
2021 Q4	$646K	Hold	2,778	–	–	0.02%	157
2021 Q3	$871K	Hold	2,778	–	–	0.03%	141
2021 Q2	$1.04M	Hold	2,778	–	–	0.03%	127
2021 Q1	$2.39M	Buy	+2,778	New	+$2.35M	0.08%	93

Other funds holding VOR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bollard Group's VOR Position: Q2 2026 in Review

Bollard Group sold out of Vor Biopharma (VOR) in Q2 2026, closing a stake of 23,987 shares — an estimated $428K sold.

Bollard Group first reported a position in VOR in Q1 2021 and held it in 21 quarters. The position peaked at $2.39M in Q1 2021. 43 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

Bollard Group reported no remaining Vor Biopharma position as of Q2 2026 after selling out during the quarter.
Bollard Group sold 23,987 Vor Biopharma shares in Q2 2026, an estimated $428K.
Bollard Group first reported a position in Vor Biopharma in Q1 2021 and held it in 21 quarters.
Bollard Group's Vor Biopharma position peaked at $2.39M in Q1 2021.
43 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Bollard Group's 13F filing for Q2 2026, filed 12 Aug 2026.